509 related articles for article (PubMed ID: 31433518)
1. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
Anastasilakis AD; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Makras P
J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.
Kondo H; Okimoto N; Yoshioka T; Akahoshi S; Fuse Y; Ogawa T; Okazaki Y; Katae Y; Tsukamoto M; Yamanaka Y; Kawasaki M; Sakai A
J Bone Miner Metab; 2020 Nov; 38(6):894-902. PubMed ID: 32656645
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.
Anastasilakis AD; Polyzos SA; Yavropoulou MP; Appelman-Dijkstra NM; Ntenti C; Mandanas S; Papatheodorou A; Makras P
Calcif Tissue Int; 2021 May; 108(5):587-594. PubMed ID: 33386953
[TBL] [Abstract][Full Text] [Related]
4. Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial.
Sølling AS; Harsløf T; Langdahl B
J Bone Miner Res; 2020 Oct; 35(10):1858-1870. PubMed ID: 32459005
[TBL] [Abstract][Full Text] [Related]
5. Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.
Sølling AS; Harsløf T; Langdahl B
J Bone Miner Res; 2021 Jul; 36(7):1245-1254. PubMed ID: 33813753
[TBL] [Abstract][Full Text] [Related]
6. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
Makras P; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Anastasilakis AD
Bone; 2020 Sep; 138():115478. PubMed ID: 32534221
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study.
Dito G; Lugaresi M; Degradi C; Guabello G; Longhi M; Corbetta S
Endocrine; 2023 Oct; 82(1):181-189. PubMed ID: 37402061
[TBL] [Abstract][Full Text] [Related]
8. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Tutaworn T; Nieves JW; Wang Z; Levin JE; Yoo JE; Lane JM
Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
[TBL] [Abstract][Full Text] [Related]
9. Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.
Clifton Goldney D; Pelegrin C; Jerkovich F; Longobardi V; Gonzalez Rodriguez E; Zanchetta MB
Osteoporos Int; 2024 Jan; 35(1):165-171. PubMed ID: 37702746
[TBL] [Abstract][Full Text] [Related]
10. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
11. The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation.
Makras P; Appelman-Dijkstra NM; Papapoulos SE; van Wissen S; Winter EM; Polyzos SA; Yavropoulou MP; Anastasilakis AD
J Clin Endocrinol Metab; 2021 Sep; 106(10):e4155-e4162. PubMed ID: 33978745
[TBL] [Abstract][Full Text] [Related]
12. Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.
Sølling AS; Harsløf T; Jørgensen NR; Langdahl B
Osteoporos Int; 2023 Mar; 34(3):599-605. PubMed ID: 36543965
[TBL] [Abstract][Full Text] [Related]
13. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Efficacy of Zoledronate Acid or Denosumab After Switching from Romosozumab in Japanese Postmenopausal Patients.
Oue T; Shimizu T; Asano T; Shimodan S; Ishizu H; Arita K; Iwasaki N
Calcif Tissue Int; 2023 Jun; 112(6):683-690. PubMed ID: 37037949
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of denosumab in men with prostate cancer.
Sølling AS; Harsløf T; Brockstedt HK; Langdahl B
Osteoporos Int; 2023 Feb; 34(2):291-297. PubMed ID: 36402867
[TBL] [Abstract][Full Text] [Related]
16. Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study.
Carr A; Kerr SJ; Richardson R; Ebeling P; Pocock N; Rojas J; Martinez E; Hoy J;
J Bone Miner Res; 2019 Dec; 34(12):2192-2197. PubMed ID: 31361922
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS).
Kang T; Park SY; Lee SH; Park JH; Suh SW
J Korean Med Sci; 2022 Apr; 37(13):e68. PubMed ID: 35380023
[TBL] [Abstract][Full Text] [Related]
18. Effects of bone remodeling agents following teriparatide treatment.
Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
[TBL] [Abstract][Full Text] [Related]
19. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
20. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.
Everts-Graber J; Reichenbach S; Ziswiler HR; Studer U; Lehmann T
J Bone Miner Res; 2020 Jul; 35(7):1207-1215. PubMed ID: 31991007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
